Novo Nordisk A/S (NVO) vs Pfizer Inc. (PFE)
- Novo Nordisk A/S NVO 38.83 −0.99%
- Pfizer Inc. PFE 29.58 +0.48%
Novo Nordisk A/S and Pfizer Inc. are both Drug Manufacturers General companies. Pfizer Inc. is the larger, with a market value of $167.8B against $131.2B — 1.3× the size. Novo Nordisk A/S trades at the lower P/E: 9.5× against 38.9×. Novo Nordisk A/S grew revenue faster over the last twelve months: 13.2% against −0.21%. Novo Nordisk A/S has the higher net margin (35.5% vs 6.80%) and the higher return on invested capital (28.7% vs 6.30%). Both pay a dividend; Pfizer Inc. yields more (5.81% vs 4.63%). Across the 23 metrics below, Novo Nordisk A/S leads on 15 and Pfizer Inc. on 8.
Valuation
Profitability
| Metric | NVO | PFE | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 80.73% | 73.18% | 72.77% |
| Operating margin | 43.36% | 21.70% | 18.77% |
| Net margin | 35.47% | 6.80% | 8.27% |
| Free cash flow margin | 14.79% | 17.25% | 17.18% |
| Return on equity | 60.84% | 4.97% | 5.87% |
| Return on assets | 22.00% | 2.13% | 2.57% |
| Return on invested capital | 28.67% | 6.30% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack